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ABSTRACT
Introduction: The increasing prevalence of
type 2 diabetes (T2DM) in the UK imposes a
significant burden on the National Health Ser-
vice (NHS). Despite the availability of effective
treatments, the loss of glycaemic control over
time results in significant comorbidities,
including nephropathy, neuropathy and
retinopathy. The cost of treating these
microvascular complications has not been well
documented, and this study aimed to provide
an accurate assessment of the healthcare
resource utilisation (HCRU) associated with
managing T2DM and its complications.
Methods: This retrospective cohort study uti-
lised electronic medical records from patients
with T2DM from the Heart of England Foun-
dation Trust (HEFT), which captures data from
patients using secondary care services. Patients
were diagnosed with microvascular complica-
tions based on ICD-10 or OPCS codes. HCRU
over a 2-year period was based on NHS Tariffs
for healthcare services for inpatient, accident
and emergency, and dialysis clinic usage.
Results: The study cohort comprised 26,629
patients with T2DM who used HEFT services
during the study period, 22.6%, 20.8% and
3.1% of whom had comorbid nephropathy,
retinopathy or neuropathy, respectively. While
the prevalence of diabetes in the overall HEFT
population was reported to be 7% in 2012,
diabetes and its associated complications
accounted for more than 30% of secondary care
costs. Furthermore, while patients with diabetes
represent only 17% of HEFT inpatients, they
account for more than 20% of service usage.
The economic burden of microvascular com-
plications increased substantially with the
severity of the condition, with the overall cost
exceeding £70 million over the 2-year period.
Conclusion: This study of patients with T2DM
in a typical secondary care provider in the UK
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showed that avoiding the progression of
microvascular complications could provide
substantial cost savings through targeted inter-
ventions that improve outcomes and lower
resource use.
Funding: Merck Sharp & Dohme Limited.
Keywords: Diabetic complications; Healthcare
resource utilisation; Insights for care;
Microvascular complications; Nephropathy;
Neuropathy; Real world data; Retinopathy;
Type 2 diabetes
INTRODUCTION
Type 2 diabetes mellitus (T2DM) accounts for
approximately 90% of all diabetes cases, thereby
contributing extensively to the burden that
diabetes imposes on individuals and healthcare
systems [1, 2]. This burden is exacerbated by the
increasing prevalence of diabetes, driven largely
by high rates of obesity and an ageing popula-
tion [3, 4]. In the UK, around 700 new cases of
T2DM are diagnosed each day, representing a
considerable challenge to the National Health
Service (NHS) [5, 6]. In 2010, the estimated cost
of T2DM in the UK was approximately £21.8
billion (£8.8 billion in direct costs and £13 bil-
lion in indirect societal costs), a figure that is
projected to rise to £36 billion (£15.1 billion in
direct costs, £20.5 billion in indirect costs) by
2035 [7]. The high prevalence of co-morbidities
in the population with diabetes [8] and com-
plications related to the disease [7] account for a
substantial proportion of this expenditure.
Despite the availability of a number of
effective pharmacological treatments, gly-
caemic control deteriorates over time, and the
resulting hyperglycaemia can result in
microvascular complications that include such
conditions as diabetic nephropathy, neuropa-
thy and retinopathy [9]. Microvascular compli-
cations are among the most common co-
morbidities associated with diabetes, and
microalbuminuria has been demonstrated to
occur in up to 26.7% of new patients with dia-
betes diagnosed in general practice [10].
Although the economic consequences of T2DM
are well documented, the contribution of long-
term microvascular complications towards
overall costs of care is poorly documented.
The Insights for Care database captures
pseudonymised (non-identifiable) patient-level
clinical and administrative data and prescribing
information from 16 distinct data sets from
multiple settings of care (primary, secondary,
tertiary, and community care and community
pharmacy) for approximately one million resi-
dents covered by the Heart of England Foun-
dation Trust (HEFT). Data are collected
quarterly from all healthcare providers within
the Trust, and refreshed on an ongoing basis, to
extend the cohort longitudinal record and
include newly diagnosed patients. The database
links all pertinent social, healthcare interven-
tion, economic and clinical outcome data, thus
allowing for a patient’s entire pathway to be
captured and collated across various care set-
tings over time, and provides a more compre-
hensive coverage of patient activity than
existing research data sets in the UK (e.g. sec-
ondary care data set, Hospital Episode Statistics
(HES) or primary care data set, Clinical Practice
Research Datalink).
As of April 2016, Insights for Care had cap-
tured over 93,000 patients with diabetes who
had used HEFT secondary care services, with an
additional 136,000 patients from the West
Midlands region who had used tertiary
retinopathy screening services at HEFT, but
secondary care services at other NHS hospital
trusts [11]. This article presents the findings of a
study using the Insights for Care database that
aims to provide an accurate assessment of the
healthcare resource usage associated with
managing T2DM and its microvascular
complications.
METHODS
This retrospective, observational cohort study
included patients with T2DM who had used
HEFT services between 2010 and 2015 and had a
minimum of 2 years’ data records, as well as
subsets of patients diagnosed with microvascu-
lar complications. Patients were selected for
cohort inclusion via ICD-10/Office of Popula-
tion Censuses and Surveys (OPCS) diagnoses
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[12, 13] (see Appendix B), and procedure and
pathology readings collated from inpatient or
outpatient electronic medical records. The
study did not require informed consent, since it
uses only pseudonymised data. However,
research ethics approval was obtained from the
National Research Ethics Service South East
England—Surrey (Reference 15/LO/0623).
To control for confounding factors that
might change over time, analyses were con-
ducted in time-delimited cohorts of the
T2DM population. The index date for eligible
patients in each microvascular complication
cohort was based on the date of the earliest
microvascular complication diagnosis during
the period between September 2010 and
2012. The cohorts included only those
patients with a minimum of 2 years of data
prior to and after the index date, in order to
maintain consistency over a fixed timeframe
for each individual. For each cohort with a
microvascular complication, a comparator
cohort was created consisting of patients
with T2DM without a diagnosis of the same
complication before or during the 2-year
period. To enable comparison of costing
periods, the median index date of the com-
plication cohort was taken as the start of the
2-year costing period for the non-complica-
tion group. Patients having a fatal event
within the study period were included in the
analysis to provide a fuller account of the
real-world cost.
Healthcare resource utilisation (HCRU) was
expressed in terms of the cost of healthcare
services to the payer (NHS), in the linked
admitted patient, accident and emergency
(A&E), and dialysis clinic data. Overall costs
were estimated using a NHS National Tariff to
allow generalizability across the NHS [14]. To
achieve this, the 2014/2015 National Tariff
Grouper was used to attach core and unbundled
healthcare resource groups to HEFT Secondary
Uses Service (SUS) data sets for inpatient, out-
patient and A&E activity. Additionally, HEFT
nephrology clinic data were used to estimate
dialysis costs not captured within SUS data,
using the NHS Best Practice Tariff as a repre-
sentative dialysis episode cost. The costs reflect
the cost of all secondary-care activity, including
those activities not typically captured in NHS
Tariff analyses (e.g. dialysis, diabetic foot
amputation and high-cost drugs).
HCRU and costs were obtained for patients
with T2DM without microvascular complica-
tions, and for those with moderate or severe
complications, as defined by ICD-10 codes,
OPCS codes, Public Health England Diabetic
Eye Screening Grade scores and estimated
glomerular filtration rate (eGFR) readings (Ap-
pendices A and B [12]; Appendix C [13]). The
number of patients with T2DM using healthcare
resources was expressed as a proportion of all
patients using HEFT in the same year (derived
from analysis of the HES data set1). Statistical
tests for differences between groups were con-
ducted using the Chi-square test with
Cramer’s V test for strength, performed as post
hoc for categorical variables (/c \0.1 consid-
ered to be not significant), and Mann–Whit-
ney–Wilcoxon test (U test) for numerical
variables (p value of B 0.05 considered to be
significant).
RESULTS
The analyses in this paper are based on
26,629 patients with T2DM and complete
medical records who used HEFT services
during the study period. The baseline char-
acteristics of the individual cohorts of those
patients with diabetic complications identi-
fied in the Insights for Care database are
shown in Tables 1, 2 and 3 and included 6021
(22.6%) with nephropathy (defined by ICD-
10 codes and eGFR readings, see appendix for
details), 824 (3.1%) with neuropathy and
5526 (20.8%) with retinopathy. Compared
with patients with no complications, patients
with moderate and severe nephropathy ten-
ded to be older and had diminished renal
function (Table 1). Patients with neuropathy
had similar characteristics to those with
nephropathy (Table 2), while patients with
moderate and severe retinopathy tended to
1 Copyright  2012, Re-used with the permission of the
Health and Social Care Information Centre. All rights
reserved.
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have been treated in secondary care for
longer (Table 3).
HCRU
While the prevalence of diabetes in the overall
HEFT population was reported to be 7% in 2012
[15], the HCRU attributable to diabetes was
higher, accounting for an estimated 31% of
secondary care costs (Fig. 1), as patients with
diabetes were more likely to be hospital users,
tended to present more frequently and received
more intensive care. Furthermore, while
patients with diabetes represented only 17% of
HEFT inpatients, they accounted for more than
20% of service usage and costs across all top 10
treatment specialities in inpatient care (Fig. 2a).
For some specialities, such as cardiology and
general medicine, the share of costs for patients
with T2DM was almost half of the total cost for
HEFT (Fig. 2b). Among the patients with dia-
betes who used HEFT services during the study
period, 22.6%, 20.8% and 3.1% of patients had
comorbid nephropathy, retinopathy or neu-
ropathy, respectively; together, these microvas-
cular complications incurred more than £72
million in costs within the 2 years immediately
post diagnosis.
Cost of Nephropathy
In the cohort of patients with T2DM and
nephropathy, increased severity was associated
with both an increased frequency of
Table 1 Patient demographics for the cohort with nephropathy (n = 6021)
Patient characteristics Patients
without
nephropathy
Patients with
moderate
nephropathy
Patients with
severe nephropathy
Comparison of patients
with severe vs no
nephropathy
Number of patients (%) 13,307 (68.8) 4996 (25.8) 1025 (5.3) –
Median (IQR) age at
index date (years)
61 (51–72) 75 (67–81) 70 (59–79) p\ 0.001a
Gender (% male) 53 48 52 NS (/c\0:1Þb
Ethnicity (% White) 63 77 64 NS (/c\0:1Þb
Ethnicity (% South Asian) 29 15 29 NS (/c\0:1Þb
Ethnicity (% other) 8 8 7 NS (/c\0:1Þb
Median (IQR) time since ﬁrst
diagnosis of diabetes in secondary
care (years)
2 (1–4) 2 (2–6) 2 (1–4) p\ 0.001a
Median (IQR) HbA1c (mmol/mol) 7.1 (6.6–8.1) 7.1 (6.6–8.0) 7.3 (6.6–8.4) p = 0.006
a
Median (IQR) cholesterol (mmol/L) 4.2 (3.6–4.9) 4.0 (3.4–4.7) 4.1 (3.5–4.9) p = 0.022a
Median (IQR) eGFR
(mL/min/1.73 m2)
87 (75–90) 55 (46–67) 37 (24–86) p\ 0.001a
Median (IQR) ACR ratio
(mg/mmol)
1.4 (0.7–3.5) 2.4 (1.1–6.8) 3.7 (1.3–11.1) p\ 0.001a
ACR urinary albumin to creatinine ratio, eGFR estimated glomerular ﬁltration rate, HbA1C glycosylated haemoglobin, IQR
interquartile range, NS no signiﬁcant difference
a Assessed using the Mann–Whitney U test
b Assessed using the Chi-square test with Cramer’s V test for strength
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interactions with HEFT (Fig. 3) and a longer
duration of inpatient stay, with an average of 19
inpatient episodes at a nephrology department
within 2 years of diagnosis. Activity levels for
the 133 patients receiving haemodialysis were
substantially higher, with an average of 140
dialysis-related attendances at HEFT over the
2 years post-index date. Inpatient interactions
were subject to the greatest increase in fre-
quency between patients without nephropathy
and patients with severe nephropathy (1.1
events versus 20.9 events over a 2-year period,
respectively), compared with outpatient inter-
actions (5.6 versus 13.1 events, respectively)
and A&E interactions (1.0 versus 2.0 events,
respectively). This increase in HCRU led to
increased costs for both inpatient and
outpatient visits with the annual cost per
patient increasing in proportion to the severity
of the condition, and costs for patients with
severe nephropathy (£2765) being almost seven
times those of the patients with no complica-
tions (Fig. 4).
Cost of Neuropathy
Severity of neuropathy in patients with T2DM
was similarly associated with an increased fre-
quency and length of interaction with HEFT,
with an average of 11 interactions over a 2-year
period (no neuropathy) rising to 50 (severe
neuropathy) (Fig. 3). This led to an increase in
costs for both inpatient and outpatient visits,
where the annual cost per patient was shown to
Table 2 Patient demographics for the cohort with neuropathy (n = 824)
Patient characteristics Patients
without
neuropathy
(n = 23,395)
Patients with
moderate
neuropathy
(n = 793)
Patients with
severe neuropathy
(n = 31)
Comparison of patients
with severe vs no
neuropathy
Number of patients (%) 23,395 (96.6) 793 (3.3) 31 (0.1) –
Median (IQR) age at
index date (years)
67 (56–77) 70 (59–79) 63 (51–72) NS (p[ 0.05)a
Gender (% male) 51 49 68 NS (/c\0:1Þb
Ethnicity (% white) 69 79 87 NS (/c\0:1Þb
Ethnicity (% South Asian) 23 17 6 NS (/c\0:1Þb
Ethnicity (% other) 8 4 7 NS (/c\0:1Þb
Median (IQR) time since ﬁrst
diagnosis of diabetes in secondary
care (years)
2 (2–5) 3 (2–4) 3 (1–4) p\ 0.001a
Median (IQR) HbA1c (mmol/mol) 7.1 (6.6–8.1) 7.4 (6.5–8.5) 7.7 (6.8–9.9) NS (p[ 0.05)
a
Median (IQR) cholesterol (mmol/L) 4.1 (3.5–4.8) 4.0 (3.4–4.8) 3.8 (3.5–4.3) NS (p[ 0.05)a
Median (IQR) eGFR
(mL/min/1.73 m2)
86 (64–90) 76 (56–90) 87 (58–90) NS (p[ 0.05)a
Median (IQR) ACR ratio
(mg/mmol)
1.7 (0.9–4.4) 2.1 (1.0–5.9) 4.4 (1.7–35.3) p = 0.036a
ACR urinary albumin to creatinine ratio, eGFR estimated glomerular ﬁltration rate, HbA1C glycosylated haemoglobin, IQR
interquartile range, NS no signiﬁcant difference
a Assessed using the Mann–Whitney U test
b Assessed using the Chi-square test with Cramer’s V test for strength
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be greater for patients with moderate or severe
neuropathy compared with patients with mod-
erate or severe nephropathy (Fig. 4). Moreover,
the average inpatient and outpatient costs per
patient with severe neuropathy were over
£8700—more than 13 times higher than for a
patient with no diagnosis of neuropathy within
the study timeframe.
Cost of Retinopathy
Although the number of outpatient appoint-
ments per patient increased as retinopathy
progressed (median number of outpatient clinic
appointments in the 2 years post-index date of
3, 5 and 7 for patients with T2DM and no
retinopathy, moderate retinopathy or severe
retinopathy, respectively), the number and
length of stay of inpatient admissions did not
differ from patients without retinopathy. How-
ever, the number of admissions to the
nephrology department (for dialysis) was
strongly correlated with retinopathy severity
Table 3 Patient demographics for the cohort with retinopathy (n = 5526)
Patient characteristics Patients
without retinopathy
(n = 15,396)
Patients with
moderate
retinopathy
(n = 4101)
Patients with
severe
retinopathy
(n = 1425)
Comparison of
patients
with severe vs no
retinopathy
Number of patients (%) 15,396 (73.6) 4101 (19.6) 1425 (6.8) –
Median (IQR) age at index date (years) 64 (54–77) 69 (59–77) 68 (57–77) p = 0.006a
Gender (% male) 50 53 52 NS (/c\0:1Þb
Ethnicity (% white) 72 69 59 NS (/c\0:1Þb
Ethnicity (% South Asian) 21 23 33 NS (/c\0:1Þb
Ethnicity (% other) 7 8 8 NS (/c\0:1Þb
Median (IQR) time since ﬁrst diagnosis
of diabetes in secondary care (years)
2 (1–3) 3 (2–7) 3 (2–8) p\ 0.001a
Median (IQR) HbA1c (mmol/mol) 7.0 (6.5–7.8) 7.3 (6.6–8.2) 7.7 (6.9–8.9) p\ 0.001
a
Median (IQR) cholesterol (mmol/L) 4.3 (3.6–5.0) 3.9 (3.4–4.6) 4.0 (3.4–4.8) p\ 0.001a
Median (IQR) eGFR (mL/min/1.73 m2) 85 (65–90) 77 (57–90) 75 (56–90) p\ 0.001a
Median (IQR) ACR ratio (mg/mmol) 1.7 (0.8–4.5) 1.8 (0.9–4.5) 2.5 (1.0–6.5) p\ 0.001a
ACR urinary albumin to creatinine ratio, eGFR estimated glomerular ﬁltration rate, HbA1C glycosylated haemoglobin, IQR
interquartile range, NS no signiﬁcant difference
a Assessed using the Mann–Whitney U test
b Assessed using the Chi-square test with Cramer’s V Test for strength
Fig. 1 Healthcare resource utilisation by patients in
HEFT with diabetes (HEFT-DM)
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(median of 0.9, 2.8 and 6.9 attendances in
2 years for patients with no retinopathy, mod-
erate retinopathy or severe retinopathy,
respectively). Accordingly, patients with T2DM
with severe retinopathy incurred higher cost per
patient (£984) compared with patients with
moderate or no retinopathy (Fig. 4).
DISCUSSION
The main finding of this study was that
microvascular complications account for a sub-
stantial proportion of HCRU and costs in
patients with diabetes and are, therefore,
important economic and clinical targets.
Crucially, enhanced diabetes care may be cap-
able of preventing their occurrence [16, 17].
This study also showed that the economic
impact of T2DM microvascular complications
increases substantially with the severity of the
complication. For example, treatment for
patients with severe nephropathy accounted for
more than a third of average inpatient costs per
patient, largely driven by the cost of
haemodialysis [18]. Moreover, the average cost
for patients with diabetic neuropathy, largely
related to diabetic foot ulcer disease [19], was
almost twice that of patients with nephropathy.
A previous study also assessed the economic
impact of diabetic nephropathy in Germany
[20]; while the study was much smaller in scale,
Fig. 2 Comparison of share of a inpatient usage with b cost per treatment specialty in patients with T2DM versus all
patients in HEFT
Fig. 3 Frequency of interactions with HEFT per patient
for different levels of severity of stages of retinopathy,
nephropathy and neuropathy
Fig. 4 Estimated cost per patient for different levels of
severity of stages of retinopathy, nephropathy and
neuropathy
Diabetes Ther (2019) 10:575–585 581
the findings were consistent with this study,
demonstrating higher costs with severe disease,
largely driven by costs of dialysis. In the USA,
costs have also been shown to rise substantially
as nephropathy progresses [21]. There is sub-
stantial evidence to show that intensive risk
factor management and the early use of
nephroprotective agents (e.g. ACE inhibitors,
angiotensin receptor blockers) can prevent or
delay progression of diabetic nephropathy, and
that they are also cost-effective [22]. Our find-
ings confirm the additional burden on health-
care resources due to these complications, and
they highlight the importance of identifying
and managing these complications in the NHS,
as efficiency becomes paramount in this finite
system.
While it might be expected that patients
with severe nephropathy would incur the
highest proportion of inpatient stays in a
nephrology department (86.7%), a similarly
high proportion was observed in patients with
both severe neuropathy (79.9%) and severe
retinopathy (69.4%). Again, these data concur
with other international reports regarding the
burden of neuropathy [23]. Although some of
this increase could be due to coexistence of
disease (e.g. renal and eye disease are widely
recognised to occur together [24]), it also
implies that any presentation with one
microvascular complication in the outpatient or
inpatient setting represents an opportunity to
screen for, or assess, other, possibly more seri-
ous, microvascular complications. Presentation
of neuropathy is varied and certainly during the
early stages the methods of screening com-
monly used are highly subjective. Optimal
methods of screening would therefore need to
be determined and entered into economic
models—for example, electrophysiological
screening identifies more cases than question-
naire or scoring tools, but will be more costly
[25].
Although the focus of this study is on
microvascular complications, the presence of
these complications is an indication of associ-
ated cardiovascular disease [26], such that risk
profiling for macrovascular disease might be
equally important in these settings. Our data
showed that patients with T2DM use a variety of
clinical services (i.e. not just endocrinology),
many of which are associated with the man-
agement of complications (cardiology,
nephrology, ophthalmology, general surgery,
trauma and orthopaedics) that account for a
significant share of all secondary care activity. It
is to be expected that prevention of these
complications would further reduce service
demand in the inpatient setting but also implies
that all such general areas should have access to
specialist diabetic services that can assess and
manage the patient globally. The proactive
assessment of complications other than those
that are the primary reason for attendance
could be valuable in preventing later
admissions.
There are some limitations in this study in
that, as diagnosis is undertaken across multiple
data sets (including retinopathy), it is likely that
the database is more accurate in identifying
local diabetes patients than non-local ones. In
addition, as the date of first diagnosis is not
currently available from primary care, and the
date of first diabetes hospital usage is likely to be
after diagnosis in many cases, using the date of
first diabetes hospital usage as a de facto diag-
nosis date would likely underestimate the time
since true diagnosis of population and may bias
the results.
Finally, patients who only use retinopathy
screening services (i.e. do not use HEFT core
services) are excluded, as retinopathy is not a
typical service provision of most major hospital
trusts. Indeed, our data showed that, while
there was a relatively stable incidence of
nephropathy and neuropathy among patients
with T2DM between 2010 and 2014, there was a
significant decrease in the incidence of
retinopathy (Fig. 5). This was possibly due to
the high number of retinopathy screenings after
the introduction of the Retinopathy Screening
Service in 2008, and a subsequent decline in the
background incidence rate due to improved
disease management.
The variation in patient characteristics, HEFT
service utilisation and economic resource usage
between groups of patients with or without
severe microvascular complications has been
assessed for statistical significance using uni-
variate statistical tests. These, therefore, do not
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control for possible confounding characteristics
such as age or the presence of other comor-
bidities, which should be investigated in future
work. Additionally, since this study encom-
passes the vast majority of HEFT patients with
diabetes (subject to the limitations discussed
above), the relatively large cohort ‘sample’ sizes
(especially for retinopathy) tend to lead to for-
mal statistical significance even when the
absolute variation between groups may not be
clinically relevant. Clinicians and health poli-
cymakers should assess the clinical meaning-
fulness of variations between groups when
considering novel pathway interventions tar-
geted at the patients considered in this study.
CONCLUSION
This study provides a comprehensive assess-
ment of the burden of microvascular compli-
cations in patients with T2DM on a typical,
large, secondary care provider in the UK. It is
clear that avoiding the progression of
microvascular complications in patients with
diabetes could provide substantial cost savings.
These findings suggest areas where targeted
interventions may improve outcomes and lower
resource use.
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